Karishma A Datye1, Daniel R Tilden2,3, Angelee M Parmar2, Eveline R Goethals2, Sarah S Jaser2. 1. Ian M. Burr Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Vanderbilt University Medical Center, 1500 21st Ave. South Suite 1514, Nashville, TN, 37212-3157, USA. karishma.a.datye@vumc.org. 2. Ian M. Burr Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, Vanderbilt University Medical Center, 1500 21st Ave. South Suite 1514, Nashville, TN, 37212-3157, USA. 3. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
PURPOSE OF REVIEW: Continuous glucose monitors (CGM) are transforming diabetes management, yet adolescents and young adults (AYA) with type 1 diabetes (T1D) do not experience the same benefits seen with CGM use in adults. The purpose of this review is to explore advances, challenges, and the financial impact of CGM use in AYA with T1D. RECENT FINDINGS: CGM studies in young adults highlight challenges and suggest unique barriers to CGM use in this population. Recent studies also demonstrate differences in CGM use related to race and ethnicity, raising questions about potential bias and emphasizing the importance of patient-provider communication. Cost of these devices remains a significant barrier, especially in countries without nationalized reimbursement of CGM. More research is needed to understand and address the differences in CGM utilization and to increase the accessibility of CGM therapy given the significant potential benefits of CGM in this high-risk group.
PURPOSE OF REVIEW: Continuous glucose monitors (CGM) are transforming diabetes management, yet adolescents and young adults (AYA) with type 1 diabetes (T1D) do not experience the same benefits seen with CGM use in adults. The purpose of this review is to explore advances, challenges, and the financial impact of CGM use in AYA with T1D. RECENT FINDINGS: CGM studies in young adults highlight challenges and suggest unique barriers to CGM use in this population. Recent studies also demonstrate differences in CGM use related to race and ethnicity, raising questions about potential bias and emphasizing the importance of patient-provider communication. Cost of these devices remains a significant barrier, especially in countries without nationalized reimbursement of CGM. More research is needed to understand and address the differences in CGM utilization and to increase the accessibility of CGM therapy given the significant potential benefits of CGM in this high-risk group.
Authors: Roy W Beck; Tonya Riddlesworth; Katrina Ruedy; Andrew Ahmann; Richard Bergenstal; Stacie Haller; Craig Kollman; Davida Kruger; Janet B McGill; William Polonsky; Elena Toschi; Howard Wolpert; David Price Journal: JAMA Date: 2017-01-24 Impact factor: 56.272
Authors: Lori M Laffel; Lauren G Kanapka; Roy W Beck; Katherine Bergamo; Mark A Clements; Amy Criego; Daniel J DeSalvo; Robin Goland; Korey Hood; David Liljenquist; Laurel H Messer; Roshanak Monzavi; Thomas J Mouse; Priya Prahalad; Jennifer Sherr; Jill H Simmons; R Paul Wadwa; Ruth S Weinstock; Steven M Willi; Kellee M Miller Journal: JAMA Date: 2020-06-16 Impact factor: 56.272
Authors: Shivani Agarwal; Lauren G Kanapka; Jennifer K Raymond; Ashby Walker; Andrea Gerard-Gonzalez; Davida Kruger; Maria J Redondo; Michael R Rickels; Viral N Shah; Ashley Butler; Jeffrey Gonzalez; Alandra S Verdejo; Robin L Gal; Steven Willi; Judith A Long Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Monica N Naguib; Elizabeth Hegedus; Jennifer K Raymond; Michael I Goran; Sarah-Jeanne Salvy; Choo Phei Wee; Ramon Durazo-Arvizu; Lilith Moss; Alaina P Vidmar Journal: Front Endocrinol (Lausanne) Date: 2022-02-25 Impact factor: 5.555